Needle Procedure Could Prevent Unneeded Surgery for Malignant Mesothelioma

surgery for malignant mesothelioma

A minimally invasive method for cancer staging could prevent unnecessary surgery for malignant mesothelioma. The method involves putting a needle into the chest behind the breast bone. This area is called the mediastinum. The mediastinum contains critical lymph nodes. The presence or absence of cancer cells in these nodes can help determine whether a patient needs surgery for malignant mesothelioma. Now, a group of Canadian doctors say an ultrasound-guided needle biopsy procedure can provide as much information as more invasive options with less risk and pain. Staging Helps Direct Surgery for Malignant Mesothelioma Most mesothelioma patients receive chemotherapy. If the patient is healthy enough and the cancer has not spread, the patient may also have surgery for malignant mesothelioma. Some … Continue reading Needle Procedure Could Prevent Unneeded Surgery for Malignant Mesothelioma »

New Tool Could Replace TNM for Predicting Pleural Mesothelioma Survival

pleural mesothelioma survival

A new visual tool could offer a better way to predict pleural mesothelioma survival after surgery than the current TNM staging system. That is the message from cancer researchers at China’s Peking University. The group conducted a study using a large US government database of information on pleural mesothelioma survival and treatment. They used the data to create a visual representation of pleural mesothelioma survival called a nomogram. Testing of the nomogram showed it was more accurate at predicting survival in patients who have mesothelioma surgery than the tool doctors normally use. Pleural Mesothelioma Survival and TNM The most popular method for “staging” cancer is called the TNM staging system. TNM stands for tumor node metastasis. With TNM, the further … Continue reading New Tool Could Replace TNM for Predicting Pleural Mesothelioma Survival »

SMRP Still Among Best Diagnostic Biomarkers for Mesothelioma

biomarkers for mesothelioma

Chinese researchers say soluble mesothelin-related peptides (SMRP) in lung fluid is still one of the best biomarkers for mesothelioma, even if it sometimes produces false positives.. SMRP has been studied extensively as a way to help diagnose mesothelioma. The most popular test to check levels of SMRPs in the body is a blood test called MESOMARK. In recent years, other biomarkers for mesothelioma have also emerged. But SMRPs are not just in the blood. A new meta-analysis of SMRPs from pleural effusions finds that they have a valuable place among top biomarkers for mesothelioma. Biomarkers for Mesothelioma: SMRPs and Others Malignant mesothelioma is a type of cancer that starts on the membranes around the lungs, heart or abdomen. SMRPs are … Continue reading SMRP Still Among Best Diagnostic Biomarkers for Mesothelioma »

Study Reveals Mesothelioma Chemotherapy May Be Underused in Older Patients

mesothelioma chemotherapy treatment

The older a mesothelioma patient is, the less likely he or she may be to receive mesothelioma chemotherapy. A new study says many older mesothelioma sufferers may be paying the price in shorter lifespans. Chemotherapy with pemetrexed (Alimta) and cisplatin is the gold standard for mesothelioma treatment. Many studies have linked it with longer mesothelioma survival. But an Australian study suggests that not enough older people are receiving mesothelioma chemotherapy. In fact, the older they are, the less likely they are to have chemotherapy for their mesothelioma. As a result, their chances of dying from malignant mesothelioma are higher. Mesothelioma Chemotherapy is Standard of Care Malignant mesothelioma is a hard-to-treat cancer with a poor prognosis. Mesothelioma chemotherapy is the primary … Continue reading Study Reveals Mesothelioma Chemotherapy May Be Underused in Older Patients »

Prophylactic Radiation Will Not Prevent Pleural Mesothelioma Metastasis

mesothelioma metastasis prevention

A UK study says prophylactic radiation of the chest wall is unlikely to prevent pleural mesothelioma metastasis.   Pleural mesothelioma is an aggressive cancer caused by asbestos. Tumors start on the lining around the lungs and can spread to the lungs and other organs. Pleural mesothelioma is the most common type of asbestos cancer. Doctors sometimes use procedures that pierce the chest wall to help diagnose mesothelioma or to deal with mesothelioma side effects. Sometimes, new mesothelioma tumors can form along the instrument tracts or in the spot where the chest wall was pierced. When tumors spread it is known as mesothelioma metastasis. Some evidence suggests that radiating the chest wall after a procedure might prevent mesothelioma metastasis in that … Continue reading Prophylactic Radiation Will Not Prevent Pleural Mesothelioma Metastasis »

New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy

mesothelioma clinical trial of dendritic cells

A Dutch company has recruited the first patients into a pivotal mesothelioma clinical trial of autologous dendritic cells. Dendritic cells are immune system cells that work as messengers. They help tell T cells to attack cancers like malignant mesothelioma. The new mesothelioma clinical trial will test using the patient’s own dendritic cells (autologous cells) as a way to keep cancer from coming back after mesothelioma treatment. Expanding Mesothelioma Treatment Options There is only one approved treatment for malignant pleural mesothelioma. This “standard of care” treatment is chemotherapy with Alimta (pemetrexed) and cisplatin. Although most mesothelioma patients receive this treatment, very few live longer than a year after diagnosis. A Netherlands-based company called Amphera is trying to change those odds. Its … Continue reading New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy »

Patients with Impaired Kidneys Could Still Take Alimta for Mesothelioma, Study Finds

Alimta for mesothelioma is kidney patients

New research in the Netherlands suggests that patients who would not normally be prescribed Alimta for mesothelioma could still benefit from the gold standard mesothelioma treatment. The key is an alternate dosing strategy. Alimta is a powerful drug that works by blocking a molecule needed for cell replication. Right now, doctors do not recommend Alimta for mesothelioma in people with poor kidney function. But Dutch pharmacology experts now say it is possible to adjust the dosing to make Alimta safer for these mesothelioma patients. Alimta for Mesothelioma: Proper Dosing is Key The FDA approved Alimta for mesothelioma in 2004. Alimta (pemetrexed) is still the only drug approved for the treatment of malignant mesothelioma. It has also been approved to treat … Continue reading Patients with Impaired Kidneys Could Still Take Alimta for Mesothelioma, Study Finds »

Quality of Life for Mesothelioma Patients Hinges on Activity and Nutrition

quality of life for mesothelioma

Muscle mass and nutrition can have a direct impact on quality of life for mesothelioma patients. That’s the finding of an Australian study of sixty-one men and women with malignant pleural mesothelioma. Researchers say the quality of life for mesothelioma patients was compromised by lower muscle mass or malnutrition. It is a wake-up call for mesothelioma patients to stay active and eat well for the best outcomes. Impacts on Quality of Life for Mesothelioma Patients Pleural mesothelioma is an incurable cancer. Even with the best mesothelioma treatments, most patients still face a grim prognosis. But there is evidence that good self-care may help. Previous studies have shown that patients with the best nutritional status often have longer mesothelioma survival. Nutritional … Continue reading Quality of Life for Mesothelioma Patients Hinges on Activity and Nutrition »

Chemotherapy During Mesothelioma Surgery: Is it Dangerous?

chemotherapy during mesothelioma surgery

A new study finds that chemotherapy during mesothelioma surgery does not raise the risk for complications. That could be good news for pleural mesothelioma patients who want to keep cancer at bay as long as possible. A group of Indian doctors compared the cases of thoracic cancer patients who had surgery with or without intraoperative chemotherapy. Only one of the “surgery + chemotherapy” patients developed a serious complication. Patients in this group also lived longer than those who did not receive intraoperative chemotherapy. When Do Doctors Use Chemotherapy During Mesothelioma Surgery? The two primary types of mesothelioma surgery are extrapleural pneumonectomy (EPP) or lung-sparing pleurectomy/decortication (P/D). Patients often have chemotherapy prior to surgery to shrink their mesothelioma tumor. Many have … Continue reading Chemotherapy During Mesothelioma Surgery: Is it Dangerous? »

Risk of Dying from Mesothelioma Varies by Type, Study Shows

Risk of dying from mesothelioma

The risk of dying from mesothelioma rises and gradually falls  in the decades after exposure for most, but not all, types of asbestos cancer. New research shows those peaks and valleys can vary based on a number of factors. Public health researchers from across Italy recently published their findings on asbestos workers’ risk of dying from mesothelioma. They suggest that the lifetime risk of dying from peritoneal mesothelioma stays high, even after the risk of death from pleural mesothelioma and lung cancer begins to drop off. Quantifying the Risk of Dying from Mesothelioma Asbestos is the primary cause of all three types of mesothelioma: pleural, peritoneal, and pericardial. Pleural mesothelioma is the most common asbestos-related cancer. Pleural tumors start on … Continue reading Risk of Dying from Mesothelioma Varies by Type, Study Shows »

Get your free copy of
“Surviving Mesothelioma” Today!